kenner schreef op 21 juni 2019 13:43:
OUTLOOK 2016
For the remainder of 2016, the Company expects:
• Investment in the production of RUCONEST® in order to ensure continuity of supply to the growing markets in the US, Europe and the rest of the world.
• Investment in the clinical trial program for RUCONEST® in prophylaxis of HAE and the
development of a sub-cutaneous version of RUCONEST®.
• We will also continue to invest carefully in the new pipeline programs in Pompe disease and Fabry’s disease, and other new development opportunities and assets as these occur. To this end, we will be expanding in a modest way at our R&D centre at Evry in France, and in our milk production sites in the Netherlands.
• Increasing selected marketing activity where this can be profitable for Pharming, such as in our current territories of Austria, Germany and the Netherlands.
• We will continue to support all our marketing partners in order to enable the maximization of the sales and distribution potential of RUCONEST® for patients in all territories, as we continue to believe that RUCONEST® represents the fastest, most effective, most reliable and safest therapy option available to HAE patients.
In 2016, 2017, 2018 niet veel bereikt. In de jaarrekening 2016, 2017 en 2018 veel van hetzelfde. Het geheel geeft ernstig te denken over vooruitgang in de ontwikkelingen van de veronderstelde mogelijkheden.
In 2019 een start van een vooronderzoek.